GSK plc 6-K, filed Aug 5, 2021
GSK plc (GSK)
6-K
2021-08-05
For: 2021-08-05
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on August 5, 2021.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of August 2021
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
GlaxoSmithKline plc
Block listing Application
Application has been made to the Financial Conduct Authority and
the London Stock Exchange plc for a total of 3,230,000 Ordinary
Shares of 25p each ('Shares') to be admitted to the Official
List.
The Shares are being reserved under an existing block listing and
will be issued under the GlaxoSmithKline plc Share Save Plan 2012
and GlaxoSmithKline plc 2017 Deferred Annual Bonus
Plan.
When issued, the Shares will rank pari passu with the existing
Ordinary Shares of 25p each.
Admission is expected to be effective on 6 August
2021.
V A Whyte
Company Secretary
5 August 2021
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: August
05, 2021
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|